CIK 0000875320
- Large accelerated filer
VERTEX PHARMACEUTICALS INC / MA
Sign in to watch- Ticker
- VRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- Operating
- EIN
- 043039129
- Phone
- +1 617-341-6393
- Business address
- 50 NORTHERN AVENUE, BOSTON, MA, 02210
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $15,378,206
- in 4 filings, $15.4M under 10b5-1 plans
Net −$15,378,206. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-02-21 | ALTSHULER DAVID EVP, Global Research and CSO | Sale | −1,843 | $294.03 | $542K | 41,146 |
| 2023-02-21 | ALTSHULER DAVID EVP, Global Research and CSO | Sale | −900 | $294.73 | $265K | 40,246 |
| 2023-02-17 | WAGNER CHARLES F JR EVP & Chief Financial Officer | Shares withheld for taxes | −3,750 | $292.85 | $1.1M | 61,441 |
| 2023-02-17 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Shares withheld for taxes | −4,498 | $292.85 | $1.3M | 60,947 |
| 2023-02-17 | Sanna Bastiano EVP, Cell & Genetic Therapies | Shares withheld for taxes | −3,750 | $292.85 | $1.1M | 55,984 |
| 2023-02-17 | Sachdev Amit EVP, Chief Patient Officer | Shares withheld for taxes | −3,498 | $292.85 | $1.0M | 68,986 |
| 2023-02-17 | Kewalramani Reshma CEO & President | Shares withheld for taxes | −9,359 | $292.85 | $2.7M | 139,355 |
| 2023-02-17 | Bozic Carmen EVP and CMO | Shares withheld for taxes | −3,750 | $292.85 | $1.1M | 66,515 |
| 2023-02-17 | Arbuckle Stuart A EVP, COO | Shares withheld for taxes | −4,498 | $292.85 | $1.3M | 71,107 |
| 2023-02-17 | ALTSHULER DAVID EVP, Global Research and CSO | Shares withheld for taxes | −3,750 | $292.85 | $1.1M | 44,248 |
| 2023-02-14 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale | −71 | $295.89 | $21K | 65,694 |
| 2023-02-14 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale | −20 | $296.48 | $6K | 65,674 |
| 2023-02-14 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale | −43 | $297.98 | $13K | 65,631 |
| 2023-02-14 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale | −135 | $299.60 | $40K | 65,496 |
| 2023-02-14 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale | −51 | $300.58 | $15K | 65,445 |
| 2023-02-14 | Sanna Bastiano EVP, Cell & Genetic Therapies | Sale | −1,902 | $300.29 | $571K | 60,013 |
| 2023-02-14 | Sanna Bastiano EVP, Cell & Genetic Therapies | Sale | −279 | $301.11 | $84K | 59,734 |
| 2023-02-14 | Arbuckle Stuart A EVP, COO | Sale | −800 | $295.84 | $237K | 81,203 |
| 2023-02-14 | Arbuckle Stuart A EVP, COO | Sale | −901 | $296.85 | $267K | 80,302 |
| 2023-02-14 | Arbuckle Stuart A EVP, COO | Sale | −560 | $298.14 | $167K | 79,742 |
Page 35 of 40 · 781 trades